2024-05-13 14:04:09 ET
Almirall, S.A. (LBTSF)
Q1 2024 Results Conference Call
May 13, 2024 04:00 AM ET
Company Participants
Pablo Divasson - Director, IR and Corporate Communications
Carlos Gallardo - Chairman and CEO
Karl Ziegelbauer - Chief Scientific Officer
Mike McClellan - CFO
Paolo Cionini] - Chief Commercial Officer, Europe and International
Conference Call Participants
Lucy Codrington - Jefferies
Alistair Campbell - Royal Bank of Canada
Thibault Boutherin - Morgan Stanley
Jaime Escribano - Banco Santander
Guilherme Sampaio - CaixaBank
Alvaro Lenze - Alantra Equities
Presentation
Pablo Divasson
Good morning to everyone on the call. Thank you for joining us to review Almirall's Q1 2024 financial results and business update. As per usual, you can find the slides to this call on the Investors section of our website at almirall.com.
Please move to Slide number 2. I would like to remind you that information presented in this call contains forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause actual results to materially differ. With that, please advance to Slide number 3. Presenting today we have Carlos Gallardo, Chairman and Chief Executive Officer; Mike McClellan, Chief Financial Officer; and Karl Ziegelbauer, Chief Scientific Officer. Carlos will start with the Q1 2024 highlights, as well as an update on our biologic growth drivers as part of our path to leadership in medical dermatology. Carlos will provide you with details on the progress of the pipeline before passing to Mike to review the financials in detail. Carlos will then conclude before opening up for a Q&A session.
I would like now to pass it over to Carlos Gallardo, our Chairman and CEO, to commence with the quarterly highlights. Please move to Slide number 5.
Carlos Gallardo
Thank you, Pablo, and good morning to everyone in the call. Most of you will be familiar with our ambition to become a leader in medical dermatology. We have made significant progress in delivering innovative products to patients with skin conditions to truly impact the lives. And we remain fully dedicated to continue to create impact with our products and support patients and the medical community....
Read the full article on Seeking Alpha
For further details see:
Almirall, S.A. (LBTSF) Q1 2024 Earnings Call Transcript